To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC

Phase 3

Completed

• Conditions: Non-small Cell Lung Cancer(NSCLC)
• Interventions: Drug: BP102, paclitaxel, carboplatin; Drug: Avastin®, paclitaxel, carboplatin

• Registration Number: NCT05169801
• Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Brief Summary

This is a randomized, double-blind, positive parallel control, multicentre Phase III clinical trial, a clinical trial of biosimilar drugs, so the type of comparison is equivalence test.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-25
• Primary Completion: 2019-10-21
• Study Completion: 2021-06-17
• Status Verified: 2021-12
• Study First Submitted: 2021-12-23
• Study First Submitted QC: 2021-12-23
• Last Update Submitted: 2021-12-23
• Study First Posted: 2021-12-27
• Last Update Posted: 2021-12-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 520

Inclusion Criteria

1. Aged from 18 to 75 (including 18 and 75), male or female;
2. Patients with locally advanced and unresectable NSCLC that has been histologically or cytologically proven, metastatic, or recurrent NSCLC.
3. No previous systematic antitumor therapy for current stage diseases. If previous adjuvant therapy has been received, it is necessary to ensure that the interval between the end of adjuvant therapy and the first administration of this study is more than 6 months, and that all adjuvant treating-related toxic reactions have recovered.
4. Patients must be able to document the EGFR mutation and ALK fusion gene status, and ALK must be negative. Patients who have not previously been tested for EGFR and ALK genes should be tested during screening;
5. There must be at least one measurable lesion as a target (according to RECIST V1.1);
6. ECOG: 0~1;
7. Life expectancy ≥24 weeks;
8. Major organs' function well.

Exclusion Criteria

1. Patients with non-small cell lung cancer of other pathological tissue types;
2. Tumor histology or cytology confirmed positive ALK fusion gene;
3. Patients with imaging evidence of tumor invasion of large blood vessels;
4. Patients with uncontrolled pleural effusion and pericardial effusion that require repeated drainage;
5. Patients with abdominal effusion;
6. During the screening period, chest CT showed tumor cavity formation, or CT scan was highly suspected of idiopathic pulmonary fibrosis, mechanized pneumonia, drug-associated pneumonia, idiopathic pneumonia or active pneumonia;
7. Patients with hypertension whose blood pressure has not been satisfactorily controlled by antihypertensive drugs, and patients with previous hypertensive crisis or hypertensive encephalopathy;
8. Have heart disease or clinical symptoms that are not well controlled;
9. Patients with unhealed wounds, active gastric ulcers or fractures;
10. Patients diagnosed with esophagotracheal fistula;
11. People with known hereditary bleeding tendency or coagulation disorder;
12. Patients with known central nervous system metastases.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment group A	BP102, paclitaxel, carboplatin	-
Treatment group B	Avastin®, paclitaxel, carboplatin	-

Primary Outcome Measures

Name	Time	Method
Objective response rate	18 weeks	optimal ORR at 18 weeks, independent radiographic assessment

Secondary Outcome Measures

Name	Time	Method
Incidence of treatment-emergent adverse events, serious adverse events	Enrollment to 28 days after permanent treatment termination	Safety analyses will be performed using the safety population, defined as all patients receiving any study drug.
Overall survival (OS)	41 months	Overall survival is defined as the time from day 1 (part 1) or from randomization (part 2) to date of death.
Disease Control Rate (DCR)	41 months	Based on investigator reviewed radiographic tumour assessment and death.
Positive rate of anti-bevacizumab antibody and its titer	41 months	Immunogenicity evaluation
Positive rate of neutralizing antibody	41 months	Immunogenicity evaluation
Progression-free survival	41 months	Progression-free survival is the time from randomization to the first documented objective disease progression (PD) using RECIST v1.1 or death due to any cause, whichever occurs first.
Duration of Response (DoR)	41 months	Based on investigator reviewed radiographic tumour assessment and death.
Quality of Life assessment using EORTC QLQ-C30	41 months	Evaluate subjects' quality of life

Trial Locations

Locations (1)

Jiangsu Cancer Hospital; 🇨🇳 Nanjing, Jiangsu, China